Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral recombinant calcitonin vs nasal calcitonin and placebo in postmenopausal osteoporosis
2008-003322-42Phase 3Completed
- Sponsor
- Tarsa Therapeutics, Inc.
- Start
- Jan 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of calcitonin salmon in postmenopausal osteoporosis (3 arms), sponsored by Tarsa Therapeutics, Inc. Primary endpoints: Lumbar spine bone mineral density (L1–L4), Bone resorption markers and 1 more. Started Jan 2009; status: completed.
02
Drugs
calcitonin salmon
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2008-003322-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003322-42.